Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Lung Cancer Treatment with Atezolizumab (Tecentriq) Immunotherapy

Lung Cancer Treatment with Atezolizumab (Tecentriq) Immunotherapy
In this article

What is atezolizumab (Tecentriq)? How does it work?

Tecentriq is designed to enhance your immune system’s ability to recognize, target and kill cancer cells. Cancer cells can sometimes evade immune cells called T cells. Atezolizumab binds cancer cells, helping the body’s T cells recognize and kill them.

Atezolizumab mechanism of action: It binds the molecule on cancer cells that inactivates immunity, PD-L1 , and is a monoclonal antibody immunotherapy drug.

atezolizumab_tecentriq_mechanism_of_action_lung_cancer_bladder_cancer_immunotherapy_pdl1 1024x678

The aim of atezolizumab treatment

Atezolizumab is given to shrink tumors, reduce disease-related symptoms and prolong survival. It is generally not given with curative intent.

Atezolizumab has so far received approval for;

In our country, it is licensed for stage 4 (metastatic) , previously treated with one line of therapy, non-small-cell lung cancer .

Tecentriq administration, dose and schedule

Atezolizumab (Tecentriq) 1200 mg/day (standard dose) is given on day 1 intravenously (I.V.), slowly over 1 hour for the first cycle. If there are no problems, after the second cycle it is administered over 30dk (minutes). Delivering medicine intravenously over a defined period is called infusion. Treatment repeats every 21 days (3 weeks).

Estimated duration of the atezolizumab (Tecentriq) regimen

  • Treatment may take up to 2 hours in the first cycle. If well tolerated, subsequent cycles take approximately 1 hour.
  • Infusion times are based on clinical studies but may vary with physician preference or tolerance. Premedications such as fluid support and intravenous (I.V.) fluids can add time.
  • Atezolizumab is generally administered in day chemotherapy units, with patients returning home afterward.
  • Treatment repeats every 21 days (3 weeks). This interval is known as 1 cycle. Treatment continues while beneficial and stops when no longer effective or when unacceptable side effects occur.

Tecentriq side effects

Possible atezolizumab-related side effects are shown below:

*Among atezolizumab patients, 4% discontinued treatment because of unwanted side effects.

- What are the side effects of immunotherapy drugs and how are they treated?

How often is follow-up necessary?

Blood checks are recommended before every treatment. Required tests include complete blood count, comprehensive metabolic panel (biochemistry), thyroid function, and blood amylase and lipase levels. Other tests may be added as the physician recommends.

How often is imaging necessary?

Imaging may be checked before treatment and every 9 weeks during treatment to assess response. It may include magnetic resonance imaging (MRI), computed tomography (CT) scans or positron emission tomography (PET) scans. After 1 year, imaging may occur every 3 months. However, both within the first 1 year and after 1 year, imaging may be earlier or later as the physician recommends.

How do blood tests or imaging affect treatment?

Depending on results, your doctor may continue atezolizumab as planned or change treatment. Its dose is not reduced for unwanted side effects.

Precautions during Tecentriq use

  • Because atezolizumab enhances your immune system’s activity against cancer, immune-mediated side effects may occur and affect healthy cells.
  • Affected organs may include the thyroid, pituitary, adrenal glands, pancreas, digestive tract, liver, lungs, skin and eyes.
  • If immunity affects healthy tissues during treatment, your doctor may prescribe a corticosteroid such as prednisone to reduce symptoms. Take it as your physician directs.
  • Your oncology pharmacist should check for interactions among your medications.

Sources

Tecentriq Full Prescribing Information - Reference ID: 4000525 - Revised: 10/2016 - fda.gov
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Lung Cancer Treatment with Atezolizumab (Tecentriq) Immunotherapy

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy